• IceCure Medical enrolled the first two patients in its ChoICE post-marketing study of ProSense cryoablation for low-risk breast cancer.
• The study targets approximately 400 patients across up to 30 U.S. sites to generate real-world evidence on the FDA-cleared treatment.
• Participating centers are expected to offer ProSense commercially to eligible patients outside the study, supporting broader adoption.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610200755PR_NEWS_USPR_____IO76413) on October 20, 2026, and is solely responsible for the information contained therein.